Tianjin Neurosurgical Institute, Tianjin Key Laboratory of Cerebrovascular and Neurodegenerative Diseases, Tianjin Huanhu Hospital, China.
FEBS Open Bio. 2020 May;10(5):904-911. doi: 10.1002/2211-5463.12849. Epub 2020 Apr 13.
Glioblastoma multiforme (GBM) and primary central nervous system lymphoma (PCNSL) are both malignant cerebral tumors; however, their treatments are vastly different. Early and precise diagnosis is vital for subsequent adequate treatment to improve prognosis. Reliable biomarkers that can easily distinguish GBM and PCNSL are urgently needed. We evaluated the diagnostic potential of lymphocyte-specific protein tyrosine kinase (LCK) as a biomarker in differentiating PCNSL from GBM using established computational approaches (Gene Expression Profiling Interactive Analysis, The Cancer Proteome Atlas, Tumor Immune Estimation Resource, GEO, Oncomine) and immunohistochemistry. The results showed that LCK was expressed at a high level in PCNSL patients but at a low level in GBM patients. Moreover, LCK expression positively correlated with the levels of infiltrating B cells in diffuse large B-cell lymphoma (DLBCL) and GBM. Overall, bioinformatics analysis and immunohistochemistry revealed that LCK expression is a potential biomarker for distinguishing PCNSL from GBM.
多形性胶质母细胞瘤（GBM）和原发性中枢神经系统淋巴瘤（PCNSL）均为恶性脑肿瘤，但它们的治疗方法却大不相同。早期和准确的诊断对于后续的充分治疗以改善预后至关重要。目前急需可靠的生物标志物来区分 GBM 和 PCNSL。我们使用已建立的计算方法（基因表达谱交互式分析、癌症蛋白质组图谱、肿瘤免疫估计资源、GEO、Oncomine）和免疫组织化学评估了淋巴细胞特异性蛋白酪氨酸激酶（LCK）作为区分 PCNSL 和 GBM 的生物标志物的诊断潜力。结果表明，LCK 在 PCNSL 患者中表达水平较高，而在 GBM 患者中表达水平较低。此外，LCK 表达与弥漫性大 B 细胞淋巴瘤（DLBCL）和 GBM 中浸润 B 细胞的水平呈正相关。总的来说，生物信息学分析和免疫组织化学表明，LCK 表达是区分 PCNSL 和 GBM 的潜在生物标志物。
